Active Ingredient(s): Pegaspargase
FDA Approved: * February 1, 1994
Pharm Company: * ENZON
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Oncaspar Overview

Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).[2] Often it is used together with anthracycline, vincristine, and prednisone.[3] It is used by injection.[3] Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.[3] Its use during pregnancy may harm ...

Read more Oncaspar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pegaspargase

Recent Oncaspar Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 750IU/ml
  • Vial: 750iu/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Oncaspar: (3 results)

Sorted by National Drug Code
  • 0944-3810 Oncaspar 750 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Baxalta Us Inc.
  • 54482-301 Oncaspar 750 [iu]/Ml Intramuscular; Intravenous Injection, Solution by Sigma-tau Pharmaceuticals, Inc.
  • 72694-954 Oncaspar 750 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Servier Pharmaceuticals

Other drugs which contain Pegaspargase or a similar ingredient: (1 result)